Immediate Impact

1 from Science/Nature 55 standout
Sub-graph 1 of 24

Citing Papers

Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery
2025 Standout
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
1 intermediate paper

Works of Jeffrey A. Bubis being referenced

DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
2024
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
2014

Author Peers

Author Last Decade Papers Cites
Jeffrey A. Bubis 78 268 29 225 135 14 380
H C Hsu 71 100 55 63 146 15 401
Bukowski Rm 59 111 50 73 48 18 424
L F Sheu 25 168 65 62 153 13 348
Baozhen Ke 183 87 15 24 192 12 444
Christina Alidousty 101 116 46 28 208 18 399
Chikako Segawa 34 112 13 39 35 10 417
Hejing Huang 26 222 36 26 101 15 358
Chun‐Jung Chang 100 132 29 43 65 15 338
Yasmin Alam 203 298 28 84 111 8 451
Katja Matthes 48 233 54 28 89 18 362

All Works

Loading papers...

Rankless by CCL
2026